ClinicalTrials.gg

Program

remlifanserin

Its studies are mostly in Hallucinations · Lewy Body Disease, led by ACADIA Pharmaceuticals.

Furthest: phase 3, since Nov 27, 20234 company-led studies, 4 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ACADIA Pharmaceuticals44 open or runningphase 3since Nov 27, 2023Nov 27, 2023Jan 2028phase 3 · NCT06159673

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2023First study: phase 3 study in HallucinationsFirst studyNCT06159673 · 1,074 planned · United States, Brazil, Bulgaria and more
  2. Dec 22, 2023Phase 3 study in HallucinationsNCT06194799 · 752 planned · United States, Brazil, Bulgaria and more
  3. Jun 12, 2025Phase 2 study in Lewy Body Dementia PsychosisNCT07029581 · 180 planned · United States, Bulgaria, Czechia and more
  4. Jul 24, 2025Phase 3 study in Lewy Body Dementia PsychosisNCT07095465 · 126 planned · United States, Bulgaria, Czechia and more

Ahead

  1. Jan 2028Primary completion: phase 3 study in HallucinationsNCT06159673
  2. Feb 2028Primary completion: phase 2 study in Lewy Body Dementia PsychosisNCT07029581
  3. Feb 2029Primary completion: phase 3 study in Lewy Body Dementia PsychosisNCT07095465
  4. Apr 2029Primary completion: phase 3 study in HallucinationsNCT06194799

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07095465Lewy Body Dementia Psychosis · United States, Bulgaria, Czechia and more3RecruitingFeb 2029126
NCT07029581Lewy Body Dementia Psychosis · United States, Bulgaria, Czechia and more2RecruitingFeb 2028180
NCT06194799Hallucinations · United States, Brazil, Bulgaria and more3By invitationApr 2029752
NCT06159673Hallucinations · United States, Brazil, Bulgaria and more3RecruitingJan 20281,074

How it is read

Names in the registry

  • “ACP-204”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.